
The FDA's plan to extend the current black box warning on antidepressants has met with opposition from the Depression and Bipolar Support Alliance (DBSA), a patient-run organization. The group charges that adding a warning of the risk of suicidal thinking and behavior in young people between the ages of 18 and 24 years could lead to higher numbers of untreated patients and potential for an increased risk of suicide.